MLAB Stock Overview
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 4/6 |
Past Performance | 1/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Mesa Laboratories, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$109.73 |
52 Week High | US$187.75 |
52 Week Low | US$82.86 |
Beta | 0.83 |
1 Month Change | 1.85% |
3 Month Change | 4.73% |
1 Year Change | -35.74% |
3 Year Change | -55.85% |
5 Year Change | -52.66% |
Change since IPO | 3,483.02% |
Recent News & Updates
Is Mesa Laboratories (NASDAQ:MLAB) Using Too Much Debt?
Mar 15Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Feb 08Recent updates
Is Mesa Laboratories (NASDAQ:MLAB) Using Too Much Debt?
Mar 15Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Feb 08Is Mesa Laboratories, Inc. (NASDAQ:MLAB) Trading At A 43% Discount?
Dec 05Is Mesa Laboratories (NASDAQ:MLAB) A Risky Investment?
Sep 28Estimating The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)
Aug 09We Think Mesa Laboratories (NASDAQ:MLAB) Is Taking Some Risk With Its Debt
Jun 28Investor Optimism Abounds Mesa Laboratories, Inc. (NASDAQ:MLAB) But Growth Is Lacking
May 31A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)
Apr 12Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?
Mar 13Estimating The Fair Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)
Dec 20Mesa Laboratories declares $0.16 dividend
Oct 03Mesa Laboratories: Softening Bottom Line Fundamentals, Fairly Priced
Sep 09Are Investors Undervaluing Mesa Laboratories, Inc. (NASDAQ:MLAB) By 41%?
Sep 06Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?
Aug 08Mesa Laboratories GAAP EPS of -$0.27 misses by $0.27, revenue of $50.45M misses by $1.72M
Aug 04Mesa Laboratories declares $0.16 dividend
Jul 07A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)
May 06Growth Investors: Industry Analysts Just Upgraded Their Mesa Laboratories, Inc. (NASDAQ:MLAB) Revenue Forecasts By 14%
Apr 09We Think Mesa Laboratories (NASDAQ:MLAB) Can Stay On Top Of Its Debt
Dec 08Shareholder Returns
MLAB | US Life Sciences | US Market | |
---|---|---|---|
7D | 3.0% | -0.2% | 0.4% |
1Y | -35.7% | 4.5% | 28.8% |
Return vs Industry: MLAB underperformed the US Life Sciences industry which returned 4.5% over the past year.
Return vs Market: MLAB underperformed the US Market which returned 28.8% over the past year.
Price Volatility
MLAB volatility | |
---|---|
MLAB Average Weekly Movement | 6.9% |
Life Sciences Industry Average Movement | 7.3% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MLAB has not had significant price volatility in the past 3 months.
Volatility Over Time: MLAB's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1982 | 698 | Gary Owens | https://www.mesalabs.com |
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. The Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in various therapeutic areas, such as screenings for hereditary diseases, pharmacogenetics, and oncology related applications.
Mesa Laboratories, Inc. Fundamentals Summary
MLAB fundamental statistics | |
---|---|
Market cap | US$578.51m |
Earnings (TTM) | US$948.00k |
Revenue (TTM) | US$212.87m |
624.4x
P/E Ratio2.8x
P/S RatioIs MLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MLAB income statement (TTM) | |
---|---|
Revenue | US$212.87m |
Cost of Revenue | US$82.57m |
Gross Profit | US$130.31m |
Other Expenses | US$129.36m |
Earnings | US$948.00k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.18 |
Gross Margin | 61.21% |
Net Profit Margin | 0.45% |
Debt/Equity Ratio | 57.8% |
How did MLAB perform over the long term?
See historical performance and comparison